


- **Atorlip** reduces total-C, LDL-C, and apo B in patients with homozygous and heterozygous FH, nonfamilial forms of hypercholesterolemia, and mixed dyslipidemia.¹
- **Atorlip** also reduces VLDL-C and TG and produces variable increases in HDL-C and apolipoprotein A-1.¹
- **Atorlip** reduces total-C, LDL-C, VLDL-C, apo B, TG, and non-HDL-C, and increases HDL-C in patients with isolated hypertriglyceridemia.¹
- **Atorlip** reduces intermediate density lipoprotein cholesterol (IDL-C) in patients with dysbetalipoproteinemia.¹

THE MOST POTENT STATIN



* Simvastatin 80mg not available at time of study.
 ** Significantly greater than mg-equivalent doses of comparative agents ($P \leq 0.01$).
 † Significantly less than atorvastatin 10mg ($P \leq 0.02$).
 ‡ Significantly less than atorvastatin 20mg ($P \leq 0.01$).

Jones P, et al, for the CURVES Investigators. *AM J Cardiol.* 1998; 81 : 582-587

The CURVES study demonstrated that atorvastatin 10, 20 and 40 mg produced greater ($P < 0.01$) reductions in LDL-C (-38%, -46%, and -51%, respectively) than milligram-equivalent doses of simvastatin, pravastatin, lovastatin, and fluvastatin in patients with elevated LDL-C after 8 weeks of treatment.²

GREATEST REDUCTION IN LDL CHOLESTEROL

“Atorvastatin causes the greatest reduction in LDL cholesterol and triglyceride concentrations.”³

GREATEST REDUCTION IN TRIGLYCERIDES

“The greatest reductions are achieved using atorvastatin in patients with high baseline triglyceride concentrations.”³

Atorlip 10 20

Atorvastatin 10 mg/20 mg Tablets

Cipla**Controls Lipids. Protects Life.****CIPLA – YOUR HEALTHCARE PARTNER SINCE 1935**

Produced by CIPLA, a leading provider of pharmaceuticals.

KEY FACTS ABOUT CIPLA:

- Supplier to the **WHO** (World Health Organisation) •
- Approved by **FDA** (USA), **MHRA** (UK) and **TGA** (Australia) •
- 25 state-of-the-art **GMP** manufacturing facilities •
- Over **1000** Formulations and **150** Active Pharmaceutical Ingredients •
- CIPLA sales reached over **USD 1 billion** in 2008-2009 •

CIPLA RANKED NO. 10 IN THE ASIA BUSINESSWEEK 50**The Asia BusinessWeek 50**

The region's top-performing companies*

COMPANY	COUNTRY	BUSINESS
1 UNILEVER INDONESIA	Indonesia	CONSUMER PRODUCTS
2 HIGH TECH COMPUTER	Taiwan	COMPUTER HARDWARE
3 LION DIVERSIFIED HOLDINGS	Malaysia	RETAILING
4 SIEMENS (INDIA)	India	COMMUNICATIONS EQUIPMENT
5 PAKISTAN PETROLEUM	Pakistan	OIL & GAS
6 STERILITE INDUSTRIES	India	METALS & MINING
7 JARDINE MATHESON HOLDINGS	Hong Kong	FINANCIAL SERVICES
8 TELEKOMUNIKASI INDONESIA	Indonesia	TELECOMMUNICATIONS
9 KOT ADDU POWER (KAPCO)	Pakistan	ELECTRIC POWER
10 CIPLA	India	PHARMACEUTICALS
11 SPARX GROUP	Japan	ASSET MANAGEMENT
12 CHIYODA	Japan	CONSTRUCTION & ENGINEERING
13 MOTECH INDUSTRIES	Taiwan	ELECTRONIC EQUIPMENT
14 ESPRIT HOLDINGS	Hong Kong	APPAREL RETAILING
15 SHIMAO PROPERTY HOLDINGS	Hong Kong	REAL ESTATE

*2007 Rankings; Based on average return of Capital and Sales Growth (over the previous 3 years).

Distributed by
 Controlled Medications Ltd
 Unit 204, 2/F New Bright Building
 11 Sheung Yuet Road, Kowloon Bay
 Kowloon, Hong Kong
 Tel: (852) 2896 0889
 Fax: (852) 2898 9842
www.stihgroup.com/conmed

conmed
 Controlled Medications Ltd.
 康德行有限公司